Business
US Justice Department indictment of Indivior Plc
US Justice Department indictment of Indivior Plc.
About this update from Reckitt Benckiser Group Plc
[{"type":"text","content":"\n \nRNS Number : 7691V Reckitt Benckiser Group PLC 10 April 2019 \n\n \n \n \n \n \n10 April 2019 \n \nUS Justice Department indictment of Indivior Plc\n \nRB Group Plc notes the 9 April 2019 indictment by the US Justice Department in relation to Indivior Plc and Indivior Inc, the pharmaceuticals business which was demerged from RB at the end of 2014\n \nThis indictment is not against RB Group Plc or any other group company and we currently have no additional or new information in respect of this matter, apart from what has been publicly issued by the Department of Justice and Indivior Plc.\n \nInvestors are referred to previous public statements including Note 19 in our 2018 Annual Report in which we state that at 31 December 2018 the company was recognising a provision (denominated in dollars) of $400m or £313m. \n \nThe information contained in Note 19 of our annual report remains our most up to date statement. \n \n \nFor further information, please contact:\n\n\n\nRB \nRichard Joyce\nSVP, Investor Relations\nJames Tilley\nDirector, Investor Relations\nPatty O'Hayer\nDirector, External Relations and Government Affairs\n\n\n+44 (0) 1753 217800\n\n\n\n\nFinsbury (Financial PR)\nPhilip Walters\n \n\n\n+44 (0) 20 7251 3801\n\n\n\n \n \n \nLEI: 5493003JFSMOJG48V108\n \n \n \n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END DOCGGUCWCUPBUBU\n ","length":4277,"tagName":"div"}]